Introduction
Mitral regurgitation is a public health problem, as the most frequent valvular disease 1 leading to frequent referrals, hospitalizations, and cardiac surgery, 2 and its burden is expected to increase with ageing of the population. 1 Degenerative mitral regurgitation (DMR) with mitral valve prolapse is the most frequent organic mitral regurgitation and the most repairable, but it is often undertreated in routine clinical practice. 3 This prevalent under treatment in both Europe and North America has multiple causes, 4 but is favoured by sub-optimal risk assessment. 2 In DMR, individual risk factors have been identified [5] [6] [7] [8] [9] [10] [11] and endorsed by clinical guidelines. 12, 13 However, while guidelines strongly recommend a combination of those risk factors in an integrated process, 12, 13 there has so far been no attempt at deriving and validating a risk score satisfying such unmet need. The lack of an integrated risk score usable at diagnosis contrasts with the availability of surgical risk scores, 14 which are nevertheless instrumental mainly in surgical decisions. Current unavailability of a mortality score in DMR should not be surprising, since very large cohorts of patients with uniform diagnosis and comprehensive clinical data are required, warranting multi-centre collaboration to obtain separate cohorts for the derivation and validation process (the two mandatory steps to obtain a score and to make it applicable to daily practice). The international MIDA registries 15, 16 provide the unique opportunity to analyse a comprehensive set of risk markers (prospectively and homogeneously collected) in an integrated manner, allowing derivation and subsequent external validation of a MIDA Score specifically applicable to DMR. Accordingly, we aimed at developing a risk score easily derivable from routinely collected clinical/echocardiographic parameters endorsed by guidelines and at validating this score externally. We also wanted to verify the hypothesis that a user-friendly MIDA mortality score is independently and incrementally predictive of shortand long-term survival after diagnosis of DMR. In summary, we aimed at providing for the first time a tool able to position a given patient within a continuous spectrum of mortality risk whether assigned to surgical treatment or to continuing medical therapy.
Methods
A fully detailed 'Methods' section is available as Supplementary material online, whereas a more concise version is reported below.
Study design
The Mitral Regurgitation International DAtabase (MIDA) registries were created by systematically merging a series of prospectively assembled electronic institutional echocardiographic databases, each originally generated to optimize echocardiographic reporting (see Appendix). All patients provided prior informed consent for anonymous publication of their clinical data; the study was conducted in accordance with institutional guidelines, national legal requirements, and the revised Helsinki declaration. The present reporting complies with the TRIPOD statement and dedicated tutorials. 17 18 General inclusion/exclusion criteria of the MIDA registries All MIDA registries share analogous general eligibility criteria: (i) inclusion of consecutive patients with primary DMR by transthoracic echocardiography; (ii) availability of a comprehensive clinical/instrumental evaluation at index echocardiography; (iii) exclusion of secondary (functional) mitral regurgitation of any aetiology, ischaemic regurgitation, significant concomitant aortic disease, mitral stenosis, active endocarditis, congenital diseases, prior valve surgery.
Derivation Cohort
Patients analysed in the Derivation Cohort were those included in the MIDA-Flail Registry encompassing 1/1/1980 to 12/31/2005. 15 Patients enrolled in the MIDA-Flail Registry fulfilled the general inclusion/exclusion criteria of the MIDA registries, but, as an additional requirement, they all received a diagnosis of DMR and flail leaflets.
Validation Cohort
The Validation Cohort consists of consecutive patients enrolled in the MIDA-BNP Registry, encompassing 1/1/2000 to 31/12/2013. 16 The MIDA-BNP Registry fulfils the general inclusion/exclusion criteria of the MIDA registries, but it additionally requires -as a specific inclusion criterion-a blood sample collection. The diagnosis of flail leaflets is not mandatory for the MIDA-BNP Registry, and both DMR and mitral valve prolapse or DMR and flail leaflets can be included. By study design, patients could be part of only one of the two cohorts.
Echocardiography
Echocardiographic data were analysed as collected at the time of echocardiography 19 without subsequent modification. The severity of DMR was based on the final diagnosis reported in the original echocardiographic report, which was performed by integrating all recorded echocardiographic parameters. 12, 13, 20 Statistical analysis
Prognostic markers analysed to create the MIDA Score were selected on the basis of their known link to outcome in DMR and their guidelinebased mention as a potential trigger for surgery (i.e. age > _65 years, left atrial diameter > _55 mm, ejection fraction < _60%, left ventricular endsystolic diameter > _40 mm, heart failure symptoms, atrial fibrillation, and right ventricular systolic pressure >50 mmHg). Hazard ratios of univariate competing risk models were estimated in the Derivation Cohort for the components of the Score. Weights for these risk factors were calculated by redoing the univariate, transition-specific HR. In order to capture the risk attached to the consequences of volume overload (rather than the nonspecific risk of death related to aging), 11 the weight for age > _ 65 years in keeping with the results of competing risk analysis was set at a value of 3 (see Supplementary material online for more explanation). For each patient the MIDA Score was calculated as the sum of these weights ( Table 2) . The predictive ability of the MIDA Score for survival under medical management was described using a Harrell's C-statistic for the survival models. 21 The C-statistic ranges from 0.5 to 1.0, with values of 0.5 indicating no predictive ability, and a value of 1.0 indicating perfect predictive ability. The C-statistic was estimated by fitting a competing risk model to the derivation data and the validation data separately.
Missing data
Since some variables may not have been detectable (e.g. systolic pulmonary pressure in the absence of tricuspid regurgitation), the main analysis was based on the clinical principle that absent or missing variables are counted as negative. As an additional analysis, multiple imputation was used to generate 10 data sets and then to average the results.
Predictive ability of the MIDA Score for 1-year mortality
Association of the MIDA Score with 1-year mortality was analysed with a logistic regression model in the Derivation Cohort and validated for the Validation Cohort. The C-statistic (Somer's D) was used to examine the predictive power of the score in the Validation Cohort.
Results
Baseline characteristics and MIDA Score in the Derivation Cohort
Baseline characteristics of 2472 patients included in the Derivation Cohort are summarized in Table 1 (left column). Flail leaflet was idiopathic in 2301 (93%) patients, caused by healed endocarditis in 171 (7%). Involvement was confined to the posterior leaflet in 1956 (79%) patients and to the anterior leaflet in 346 (14%), while both leaflets were involved in 170 (7%) patients. During follow-up (9.2 ± 5.4 years), 960 deaths occurred (390 under medical management). Overall survival at 10 years was 68 ± 1% (56 ± 2% in patients symptomatic at diagnosis).
At univariate analysis, symptom presence, ejection fraction < _60%, left-ventricular end-systolic diameter > _40 mm, atrial fibrillation presence, right ventricular systolic pressure > _50 mmHg, left atrial diameter > _55 mm, and age > _65 years were all associated with survival Table 2 .
In the Derivation Cohort, the median MIDA Score was 4 (25th-75th percentile: 2-6) ( Table 3 
Baseline characteristics and MIDA Score in the Validation Cohort
Baseline characteristics of the Validation Cohort (n = 1194) and MIDA Score distribution are depicted in Tables 1 and 3 , respectively. When compared to the Derivation Cohort, patients included in the Validation Cohort were more often symptomatic, although showing less severe consequences of DMR. These findings can be explained by the limited reproducibility of symptom assessments, the higher prevalence of female patients in the Validation Cohort, and the higher use of beta-blockers rather than digoxin in this group. 22 During a follow-up of 4.8 ± 2.4 years, 191 deaths occurred (131 under medical management). Overall survival at 10 years was 68 ± 5% (59 ± 7% in patients symptomatic at diagnosis). Surgery was eventually performed in 725 patients (93% repair).
Competing risk analysis confirmed the MIDA Score to be regardless of age associated with long-term risk of death under medical management (adjusted HR (Figure 1 
Specific outcomes in the Combined Cohort
Since remarkably similar 5-and 10-year survival rates were recorded and an analogous prognostic ability of the MIDA Score had been confirmed, we combined Derivation and Validation Cohorts to further increase the sample size in order to facilitate long-term follow-up and sub-group analyses. Baseline characteristics of the Combined Cohort are reported in Tables 1 and 3 , respectively. During a follow-up of 7.8 ± 5.0 years, 1151 patients died. Overall survival at 5 and 10 years was 84 ± 1 and 69 ± 1% years, respectively. 
During a medical follow-up of 2.1 ± 3.5 years, 521 patients died. Figure 2 reports the independent association of the MIDA Score with mortality under medical management in selected sub-groups. Longterm survival according to the categories of MIDA Score is depicted in Figure 3A and (using multiple imputation) in Figure 4A (see Supplementary material online).
Surgery was eventually performed in 2659 patients (90% repair). During a post-surgical follow-up of 7. 1.71% in those who survived, P = 0.004); 1.99% in those who were treated exclusively medically (vs. 1.62% in those who were operated on, P < 0.001).
When the post-surgical outcome was analysed, the MIDA Score retained its independent prognostic significance from age and Figure 3B and using multiple imputation in Figure 4B 
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Discussion
The management of DMR-and particularly the indications for surgery-mainly relies on symptoms and/or echocardiographic measurements providing specific cut-offs reflecting the magnitude of volume overload consequences. Physicians are invited by guidelines to search for the presence of any of those during decision-making, but the highly relevant therapeutic consequences deriving from ascertaining the presence of even one risk factor (which may lead 'per se' to a surgical decision) likely favour DMR under treatment. At the same time, while the operative risk in a given patient is predictable through specific mortality scores, the mortality risk of continuing medical treatment for the same patient is not yet definable.
We analysed the outcome of two cohorts totalling an unmatched sample of 3666 patients, all affected by DMR, to build a risk score integrating the presence of risk factors endorsed by scientific guidelines and their clinical weight. The MIDA Score we derived and validated was able to position a given patient within a continuous spectrum of mortality risk, before or after surgery, at short-and long-term. Because we found a considerable difference in mortality between the MIDA Score levels, our data indicate that the MIDAScore could generate highly relevant clinical information, of independent prognostic value and incremental to known indicators of current guidelines for the management of DMR.
The EuroSCORE II was significantly higher in patients who were treated exclusively medically as compared to those who received a mitral operation. Taken together, our findings suggest that physicians may underestimate the spontaneous high risk of patients left under medical management, due to the lack of tools defining the risk incurred under such circumstances. By accurately defining not just long-term outcome but also the short-term and 1-year survival under medical management, the MIDA Score could contribute in preventing delays in treating higher risk patients. 13 We found that the MIDA Score retains its prognostic value within each subset of patients categorized by EuroSCORE II (Take home figure and Figure 5 ), indicating that in the context of a known risk marker, the MIDA Score maintains an incremental prognostic predictive value. Percutaneous treatment of DMR represents an increasingly used therapeutic option. 23 Whether a percutaneous treatment of DMR could represent a better strategy as compared to traditional surgery Model discrimination expresses the extent to which the model itself is capable of differentiating patients who have experienced events and it is commonly assessed using the C-statistic. 26 We found a C-stat- Figure 1) . Whether the addition of parameters deriving from cardiopulmonary exercise tests or the use of peptides (currently not yet considered mandatory by guidelines) may enhance the overall performance of the MIDA Score needs to be tested. 29 Concerning the strength and limitations of the present study, the MIDA Score was derived from the MIDA registries, which although representing the largest international multi centre registries specifically designed to study DMR, are not necessarily immune from the risk of selection bias. It is reassuring that all prognostic indicators endorsed by American and European scientific guidelines were confirmed as being valid in the present analysis.
Concerning the validity of the study findings, we decide to use external validation, which is particularly demanding but at the same time the method with the greatest clinical relevance. 30 The MIDAScore provides good discrimination, but no therapeutic decision making should exclusively rely on a single number, and should rather be based on an integrated clinical approach. 13 Since the vast majority of the study patients had severe DMR, the role of the MIDA Score in non-severe DMR-although confirmed at subgroup analysis-needs further investigations.
In conclusion, DMR management requires extensive prognostic assessment. 12, 13 The MIDA Score, developed using the largest cohorts of DMR medically and surgically treated ever analysed, can for the first time position a given patient within a continuous spectrum of short-and long-term mortality risk, overall, under medical management and after surgery, providing incremental and independent prognostic information. Our findings-generated by analysis of data collected at multiple centres from different continents-may contribute to improve DMR management, by not only facilitating guidelines application but also providing a useful tool to test new therapeutic options for patients with DMR in homogeneous categories of risk.
